US 12,275,688 B2
Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
Kristin Patterson, Stamford, CT (US); Jiping Liu, Stamford, CT (US); Ricky Wayne Couch, Durham, NC (US); Peter Gregory Varlashkin, Durham, NC (US); Mai Li, Greenville, SC (US); and Yonghong Gan, Simpsonville, SC (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics, Inc., Stamford, CT (US)
Filed on Jan. 16, 2024, as Appl. No. 18/413,575.
Application 18/413,575 is a continuation of application No. 17/806,821, filed on Jun. 14, 2022, granted, now 11,884,610.
Application 17/806,821 is a continuation of application No. 17/393,144, filed on Aug. 3, 2021, granted, now 11,427,534, issued on Aug. 30, 2022.
Application 17/393,144 is a continuation of application No. 17/177,966, filed on Feb. 17, 2021, granted, now 11,084,780, issued on Aug. 10, 2021.
Prior Publication US 2024/0190815 A1, Jun. 13, 2024
Int. Cl. A61K 31/16 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61P 35/00 (2006.01); C07C 259/10 (2006.01)
CPC C07C 259/10 (2013.01) [A61K 9/0095 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A capsule comprising:
a. about 1 mg of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide of Formula (I)

OG Complex Work Unit Chemistry
wherein the N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide constitutes about 0.1 wt/wt % to about 7 wt/wt % of the capsule;
b. about 50 wt/wt % to about 98 wt/wt % of one or more diluents;
c. about 1 wt/wt % to about 10 wt/wt % of one or more disintegrants; and
d. about 0 wt/wt % to about 5 wt/wt % of one or more lubricants.